Vida rolls out analysis services for clinical trials

By The Science Advisory Board staff writers

May 17, 2022 -- Lung imaging software developer Vida Diagnostics has introduced a suite of retrospective data analysis services for sponsors of clinical trials at this week's American Thoracic Society conference in San Francisco.

Designed to yield insights about therapeutic mechanisms of action and/or characteristics of a responder population, the new artificial intelligence (AI)-based offering enables clinical trial sponsors to utilize Vida's biomarker generation services, according to the vendor. Vida offers more than 50 biomarkers, including new chest and vascular imaging biomarkers.

Available for both prospective clinical trials and respective datasets, the new chest imaging biomarkers include airway biomarkers for mucus plug scoring, bronchiectasis scoring, and total airway count, according to the vendor. Other new functional chest imaging biomarkers include respiratory airflow dynamics and ventilation defect probability mapping. Vida has also incorporated coronary artery calcium score as a new vascular biomarker.

Vida Ventures adds $825M to portfolio
Vida Ventures announced the closing of Vida Ventures III on $825 million in an oversubscribed fund. The company now has over $1.7 billion of...

Copyright © 2022

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter